Swiss Biotech Acquires Maker Of Celiac Drug Nearing Trials

Law360 (September 11, 2019, 5:28 PM EDT) -- Swiss biotech Anokion SA announced Wednesday that it has acquired Massachusetts-based Kanyos Bio Inc., which was formed in collaboration with Anokion in 2015 and is working toward development of a treatment for celiac disease.

Both companies are pursuing antigen-specific treatments for autoimmune diseases. Anokion said in a news release that it has completed a $40 million Series B financing that will allow both Kanyos' celiac drug and Anokion's lead product to treat multiple sclerosis to begin the clinical trial process within the next year.

The joint entity plans to file an investigational new drug application with the U.S. Food and Drug...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS